There’s no question, however, that the decision to abandon the twice-daily version introduces a significant delay to Pfizer’s plans to enter the obesity market, which has been transformed in ...
Pfizer (PFE) offered up some more details on its weight loss drug pipeline on Tuesday during a call with investors after it ...
Yet that hasn’t been enough to appease investors who have worried that Pfizer missed the boat on booming demand for obesity ... of the year, a twice-daily version of a second pill was shelved.
Morgan Stanley estimated that the global market for obesity ... once-daily version of its oral, modified-release GLP-1 agonist, after a twice-daily version had resulted in a high rate of drop ...
AstraZeneca said its experimental weight loss pill was well tolerated by patients in an early-stage clinical trial.
Kishida told reporters he had arranged to secure 2 million doses of Pfizer's antiviral pill in a call with CEO Albert Bourla. Japan will aim to get boosters to about 31 million healthcare workers ...
Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...
(Bloomberg) -- Obesity ... daily at the highest dose to adults with obesity, according to a mid-stage study published last year. Drugmakers including Pfizer Inc. and AstraZeneca Plc also have ...
Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for its experimental obesity pill ... doses given daily of Viking’s ...
Oct 22 (Reuters) - The U.S. Food and Drug Administration on Tuesday approved Pfizer's (PFE.N), opens new tab RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in ...
A group of lawmakers led by Sen. Dick Durbin (D-Ill.) demanded answers from Pfizer and Eli Lilly about their relationships with the telehealth prescribers they point patients to from their ...